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Abstract
Background: It has been long debated whether menopause itself is a risk factor for hypertension in peri-menopausal
women. We aimed to assess the association between menopause and hypertension, and whether metabolic syndrome
(MetS) has an influence on its effect.
Methods: Data for 1502 women aged 42 to 53 from the Korean Genome and Epidemiology Study (KoGES) database
were retrospectively analyzed. The KoGES database consists of 10,038 participants, of which 52.6% (5275) were female.
Subjects were followed up for 4 years, and compared according to menopausal status. Additionally, 1216 non-
hypertensive subjects were separately analyzed to assess whether a change in menopausal status was associated with
development of hypertension.
Results: The prevalence of hypertension, diabetes, and MetS for menopausal and non-menopausal subjects at baseline
was 24.4% vs. 16.7%, 5.8% vs. 2.9%, and 25.4% vs. 16.6%, respectively (p < 0.01 for all comparisons). Among non-
hypertensive subjects at baseline, prevalence of hypertension at 4-year follow-up was 9.4%, 19.7%, and 13.1% for non-
menopausal, those who became menopause during follow-up, and those who were menopause at baseline,
respectively. Development of hypertension was positively correlated with MetS (HR 3.90, 95% CI 2.51–6.07) and
increased BMI (HR 1.09, 95% CI 1.03–1.16), while association with menopause was not significant.
Conclusions: Menopause is closely associated with increased incidence of hypertension, but the increase may not be
attributable to menopause itself but to increased prevalence of MetS.
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Background
Hypertension is a well-known risk factor of cardiovascular
disease [1], and about a quarter of the global population
over 20 years of age have been diagnosed [2]. The preva-
lence of hypertension increases with age, and women have
a lower prevalence of hypertension up to the sixth decade.
However, the prevalence increases rapidly as women enter
the fourth and fifth decades, surpassing that of men in the
sixth and seventh decades [3]. This demographic trend is
observed in both Western and Asian countries [4].
Researchers have conducted studies in order to analyze
the factors contributing to increased prevalence of hyper-
tension in middle-aged women, and some have suggested
menopause as a potential risk factor [5–7]. However, other
studies suggest differently, that there exists no correlation
between menopause and hypertension [8, 9].
Women undergo several metabolic changes near meno-
pausal age. Hormonal changes causes the body to accu-
mulate abdominal fat, leading to central obesity, which is
a key factor of metabolic syndrome (MetS) [10, 11]. In a
study using data from United States National Health and
Nutrition Examination Survey (NHANES), postmeno-
pausal status increased the risk of MetS by 60% after
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adjustment for age, body mass index (BMI), and other
confounding variables [12]. As menopause and MetS are
closely related, it is possible that the increase in prevalence
of hypertension is attributable to metabolic changes re-
lated to MetS, which is prevalent in 30 to 40% of women
after menopause [13, 14].
In this retrospective analysis, we sought to investigate
the association between menopause and hypertension by
analyzing data from the Korean Genome and Epidemi-
ology Study (KoGES).
Methods
KoGES database
The KoGES cohort provides valuable evidence for pre-
vention of major chronic diseases such as hypertension,
obesity, diabetes, etc. It collects epidemiological, bio-
logical, and clinical data through questionnaires from
participants aged 40 to 69, and also includes data on
lifestyle, family history, and nutritional status. Clinical
examinations are performed on a regular basis, and bio-
logic specimens such as blood, urine, and DNA are col-
lected [15]. The details of the cohort have been
previously published in a separate article [15, 16].
Study design
The KoGES database included 5275 female (52.6% of
10,038) subjects at baseline. The mean menopausal age
was 47.8 ± 5.2, and subjects with ages in the range of 1
standard deviation from mean (ages 42 to 53) were se-
lected (n = 2345). Subjects who had not completed the
4-year follow-up were excluded, and 1502 subjects were
finally analyzed for outcome. Details of the study design
are provided in Fig. 1.
Outcome analysis
The association between baseline menopausal status and
development of hypertension during the study period was
assessed. Risk factors for development of hypertension
were analyzed and compared according to menopausal
status. A subgroup of patients who were not hypertensive
at baseline separately analyzed.
Variable definitions
Blood pressure was measured in both arms using a stand-
ard mercury sphygmomanometer after resting for at least
10 min. The average of two measurements, acquired with
a 5-min interval was used for analysis. Hypertension was
defined as systolic blood pressure (SBP) ≥140 mmHg or
diastolic blood pressure (DBP) ≥90 mmHg and prehyper-
tension as SBP ≥120 mmHg or DBP ≥80 mmHg [17, 18].
Blood pressure was measured in the sitting position, and
the average value was used. Subjects with previous history
of hypertension, or those on anti-hypertensive medica-
tions were defined as hypertensive.
Diabetes mellitus was defined if the subject had at
least one of the following: (i) fasting plasma glucose
≥126 mg/dL, (ii) two-hour plasma glucose ≥200 mg/dL
during a 75 g oral glucose tolerance test [19], and (iii)
HbA1c ≥6.5%. Subjects on insulin or oral hypoglycemic
agents were also categorized as having diabetes.
MetS was defined using the modified National Choles-
terol Education Program Adult Treatment Panel III
(NCEP-ATP III) guideline [20, 21], with values for waist
circumference modified to the Korean standard reported
by the Korean Society for the Study of Obesity [22]: (i)
central obesity (waist circumference > 85 cm in women),
(ii) hypertriglyceridemia (fasting triglyceride ≥150 mg/dL),
(iii) low high density lipoprotein-cholesterol (HDL-C)
(HDL-C < 50 mg/dL for women), (iv) raised blood pres-
sure (SBP ≥130 mmHg, DBP ≥85 mmHg, or current use
of antihypertensive medications), and (v) fasting plasma
glucose concentration ≥ 100 mg/dL or current use of dia-
betes medications.
Menopause was defined as having periods of 3 months
or more without menstruation, and age at menopause
was also recorded.
Fig. 1 Study Design
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Statistical analysis
Continuous variables are reported as means ± standard
deviation, and categorical variables are reported as per-
centages of the total population. Student’s t-test was
used for comparison of continuous variables, and
one-way ANOVA or chi-square test were used for cat-
egorical variables. Univariate regression analysis was per-
formed for non-hypertensive patients at baseline to
assess risk factors associated with development of hyper-
tension. Multivariate regression analysis using variables
such as age, menopausal status, BMI, and MetS was per-
formed. For multivariate analysis, stepwise backward
elimination by likelihood ratio was conducted (probabil-
ities of stepwise entry and removal were both 0.05). For
every statistical analysis, two-sided p value lower than
0.05 was defined as statistically significant. All analyses
were performed using IBM SPSS Statistics version 22
(SPSS Inc., Chicago, IL, USA).
Ethics
KoGES was conducted in conformity with the Declaration
of Helsinki. The institutional review boards of the Korea
Centers for Disease Control and Prevention, Ajou
University Hospital (IRB No. AJIRB-CRO-06-039), and
Korea University Ansan Hospital (IRB No. ED0624)
approved of the study. Informed consent was obtained
from all subjects. This retrospective analysis using the
KoGES cohort was separately approved by Seoul National
University Hospital (IRB No. 1607–102-776).
Results
Baseline and 4-year follow-up characteristics
Among 1502 subjects, 464 were menopausal at baseline
while 1038 were pre-menopause. Menopausal subjects were
older (49.2 ± 3.1 vs. 45.4 ± 2.7 years, p < 0.001), more obese
[BMI (25.0 ± 3.2 kg/m2 vs. 24.6 ± 3.2 kg/m2, p = 0.04), had
higher values for waist circumference (81.1 ± 9.2 cm vs.
78.6 ± 8.7 cm, P < 0.001)], and had higher lipid profiles [TG
(148.4 ± 94.2 mg/dL vs. 129.1 ± 71.4 mg/dL, P < 0.001),
total cholesterol (195.9 ± 36.0 mg/dL vs. 182.1 ±
31.0 mg/dL, P < 0.001)] than non-menopausal subjects.
Baseline demographic details are summarized in Table 1.
At the 4-year follow-up period, 830 subjects were meno-
pausal while 672 were not. The demographics of meno-
pausal and non-menopausal subjects were similar to that
of the baseline survey (Additional file 1: Table S1).
Prevalence of hypertension, diabetes mellitus, and MetS
The prevalence of hypertension in menopausal and
non-menopausal subjects at baseline was 24.4% and
16.7%, respectively (P < 0.001, Fig. 2a). Diabetes mellitus
(5.8% vs. 2.9%, P = 0.006, Fig. 2b) and MetS (25.4% vs.
16.6%, P < 0.001, Fig. 2c) were also more frequent in
menopausal than non-menopausal subjects at baseline.
The trend of higher prevalence of hypertension, dia-
betes, and MetS in menopausal subjects were also con-
sistent at the 4-year follow-up period (34.7% vs. 21.7%
for hypertension, 8.7% vs. 4.0% for diabetes, and 27.6%
vs. 15.0% for Mets, all P < 0.001) (Fig. 3).
Table 1 Baseline characteristics according to menopausal status
Non-menopause (N = 1038) Menopause (N = 464) p-value
Age (years) 45.4 ± 2.7 49.2 ± 3.1 < 0.001
Weight (kg) 59.5 ± 8.1 60.0 ± 8.3 0.262
Height (cm) 155.4 ± 5.2 154.9 ± 5.0 0.063
BMI (kg/m2) 24.6 ± 3.2 25.0 ± 3.2 0.040
SBP (mmHg) 114.3 ± 16.0 118.2 ± 18.0 < 0.001
DBP (mmHg) 75.9 ± 10.7 78.9 ± 11.5 < 0.001
Waist circumference (cm) 78.6 ± 8.7 81.1 ± 9.2 < 0.001
TG (mg/dL) 129.1 ± 71.4 148.4 ± 94.2 < 0.001
Total cholesterol (mg/dL) 182.1 ± 31.0 195.9 ± 36.0 < 0.001
HDL-cholesterol (mg/dL) 46.8 ± 9.8 46.2 ± 9.9 0.242
Fasting glucose (mg/dL) 81.7 ± 9.0 82.1 ± 9.1 0.499
HbA1c (%) 5.5 ± 0.4 5.6 ± 0.4 < 0.001
Alcohol consumption (%) 31.5 28.9 0.308
Hypertension prevalence (%) 16.7 24.4 < 0.001
Diabetes prevalence (%) 2.9 5.8 0.006
MetS prevalence (%) 16.6 25.4 < 0.001
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, TG triglyceride, MetS metabolic syndrome. Data are presented as mean ± SD for
continuous variables and percentages for categorical variables
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Fig. 2 Prevalence of (a) hypertension, (b) diabetes mellitus, and (c) metabolic syndrome at baseline. HTN, hypertension; DM, diabetes mellitus;
MetS, metabolic syndrome
Fig. 3 Prevalence of (a) hypertension, (b) diabetes mellitus, and (c) metabolic syndrome at 4-year follow-up. HTN, hypertension; DM, diabetes
mellitus; MetS, metabolic syndrome
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Subgroup analysis of non-hypertensive subjects
Subjects who were not hypertensive at baseline were separ-
ately analyzed and compared according to change in meno-
pausal status. Among 1216 non-hypertensive subjects, 351
were menopause at baseline, and 282 subjects went
through menopause during the 4-year follow up period.
Subjects who were menopause at baseline, and those
who underwent menopause during follow-up had in-
creased values for waist circumference (81.0 ± 8.2 cm,
81.5 ± 8.8 cm vs. 78.9 ± 7.9, p < 0.001), total cholesterol
(202.7 ± 31.4 mg/dL, 201.8 ± 36.0 mg/dL vs. 189.0 ±
31.7 mg/dL, p < 0.001), and TG (125.9 ± 75.9 mg/dL,
127.2 ± 73.7 mg/dL vs. 103.5 ± 71.6 mg/dL, p < 0.001),
compared to those who were non-menopausal during
the study period (Table 2).
After 4 years, subjects who underwent menopause
and those who were menopause at baseline showed a
higher incidence of hypertension compared to
non-menopausal subjects (16.3%, 13.1%, and 10.1%,
respectively, p = 0.032) (Fig. 4a). The prevalence of
diabetes and MetS were also higher in menopausal
subjects at follow-up (Fig. 4b, c).
Risk factors for development of hypertension
Univariate logistic regression analysis performed on the
whole study population showed that age (OR 1.07, 95%
CI 1.01–1.12), undergoing menopause during the study
period (OR 1.73, 95% CI 1.14–2.62), increased BMI (OR
1.16, 95% CI 1.10–1.22), and MetS (OR 5.08, 95% CI
3.38–7.64) were associated with an increased risk of de-
veloping hypertension. However, multivariate regression
analysis using the same variables showed that only BMI
(OR 1.09, 95% CI 1.03–1.16) and MetS (OR 3.90, 95%
CI 2.51–6.07) were significantly associated after adjust-
ment (Table 3).
Discussion
Menopause is widely acknowledged to be associated with
increased prevalence of hypertension in peri-menopausal
women. However, our analysis suggests that increased
prevalence may be attributable to increased BMI or
presence of MetS, rather than menopause itself.
Cross-sectional analysis at baseline and 4-year follow-up
showed higher values of systolic and diastolic blood pres-
sure in menopausal women. Moreover, most components
constituting the modified NCEP-ATPIII criteria for MetS
were more inclined to be positive in menopausal than
non-menopausal subjects. In a longitudinal observation of
subjects who were non-hypertensive at baseline, being
menopause at the end of the period was associated with
higher prevalence of hypertension, diabetes, and MetS.
However, according to multivariate analysis assessing for
risk of hypertension, the effect of menopause was insig-
nificant after adjusting for other variables such as age.
This finding suggests that the popular belief that meno-
pause itself is a factor in development of hypertension in
peri-menopausal women might not always be true. On the
other hand, increased BMI and prevalence of MetS were
associated with a significantly increased risk for develop-
ment of hypertension, implying that not menopause per
se, but increased BMI and MetS may be important factors
behind hypertension. Controlling obesity and glucose
Table 2 Four-year follow-up characteristics of non-hypertensive subjects at baseline
Total Change in menopausal status
Non-menopause after
4 years (N = 583)
Menopause after
4 years (N = 282)
Menopause at baseline
(N = 351)
P-value
Age (years) 50.1 ± 3.2 48.2 ± 1.9 51.0 ± 2.8 52.7 ± 3.2 < 0.001
Weight (kg) 58.7 ± 7.5 58.5 ± 7.4 58.7 ± 7.1 59.0 ± 8.1 0.677
Height (cm) 155.5 ± 5.2 155.7 ± 5.2 155.5 ± 5.6 155.1 ± 5.2 0.206
BMI (kg/m2) 24.3 ± 3.0 24.1 ± 2.9 24.3 ± 2.7 24.5 ± 3.1 0.184
Waist circumference (cm) 80.2 ± 8.3 78.9 ± 7.9 81.0 ± 8.2 81.5 ± 8.8 < 0.001
HbA1c (%) 5.4 ± 0.5 5.3 ± 0.4 5.4 ± 0.5 5.5 ± 0.6 < 0.001
Fasting glucose (mg/dL) 88.4 ± 12.3 87.2 ± 9.0 89.1 ± 13.5 89.8 ± 15.6 0.005
Total cholesterol (mg/dL) 195.8 ± 33.6 189.0 ± 31.7 202.7 ± 31.4 201.8 ± 36.0 < 0.001
HDL-cholesterol (mg/dL) 47.1 ± 10.3 47.6 ± 10.4 46.5 ± 9.5 46.8 ± 10.8 0.334
TG (mg/dL) 115.6 ± 74.1 103.5 ± 71.6 125.9 ± 75.9 127.2 ± 73.7 < 0.001
Alcohol consumption (%) 30.8 34.8 25.2 28.5 0.009
Diabetes (%) 5.5 3.1 5.7 9.4 < 0.001
MetS (%) 15.1 10.3 19.5 19.7 < 0.001
Hypertension (%) 12.9 10.1 16.3 13.1 0.032
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, TG triglyceride, MetS metabolic syndrome. Data are presented as mean ± standard
variables for continuous variables and percentages for categorical variables
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tolerance, which are key factors of MetS, could be the key
in preventing hypertension in this specific population.
There have been contradicting opinions on the role of
menopause in development of hypertension. Historically,
age, increased BMI, and menopause have been suggested
as significant risk factors for hypertension in
peri-menopausal women [23, 24]. Staessen et al. empha-
sized menopause as an important contributor of hyper-
tension even after adjusting for age and BMI [5]. Their
studies suggested that menopause was related to systolic,
rather than diastolic hypertension, with the hypothesis
that menopause decreased the compliance of large
arteries through decrease in estrogen [6]. Findings of
Zanchetti et al. also supported the effect of menopausal
event on hypertension [7]. However, Casiglia et al. on
the other hand, maintained that the effect of menopause
on hypertension became negligible when adjusted for
age [8]. Portaluppi et al. reported that increased BMI
and older age, but not menopause were risk factors for
hypertension in women near menopausal age [24]. Our
study results suggest that increased BMI and prevalence
of MetS are significant risk factors of developing hyper-
tension in peri-menopausal women. Previous studies
have also sought to address the relationship between
obesity, menopause and hypertension, but their ap-
proach toward obesity was limited. Although BMI calcu-
lation is the simplest and most common way to evaluate
obesity, it does not capture the metabolic and structural
changes behind obesity such as dyslipidemia and abdom-
inal obesity, which are frequently prevalent near meno-
pausal age [25–27]. As there are evidence that central
obesity is an independent risk factor of cardiovascular
disease regardless of overall obesity [28], we used the
prevalence of MetS to embrace the metabolic changes as
a potential risk factor of development of hypertension in
peri-menopausal women.
Pathogenesis of MetS has close relationships with vis-
ceral obesity and insulin resistance, which are key
Fig. 4 Change in prevalence of (a) hypertension, (b) diabetes mellitus, and (c) metabolic syndrome at 4-year follow-up in initially non-
hypertensive patients. HTN, hypertension; DM, diabetes mellitus; MetS, metabolic syndrome
Table 3 Risk for development of hypertension
Univariate analysis OR 95% CI Multivariate analysis OR 95% CI
Age 1.065 1.011–1.121 Age 1.040 0.971–1.115
Menopause after 4 years 1.731 1.143–2.622 Menopause after 4 years 1.391 0.863–2.242
Menopause at baseline 1.339 0.888–2.019 Menopause at baseline 0.965 0.565–1.647
BMI 1.157 1.097–1.220 BMI 1.093 1.031–1.159
MetS 5.080 3.377–7.642 MetS 3.736 2.396–5.827
OR odds ratio, CI confidence interval, BMI body mass index, MetS metabolic syndrome
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mechanisms that increase your blood pressure. Visceral
obesity is suggested to cause hypertension via various
mechanisms. Abdominal visceral fat increases sympa-
thetic nerve activity in muscles [29]. Visceral fat also
serves as an endocrine organ releasing adipocytokines
such as leptin, resistin, TNF-α, and IL-6. These factors
contribute to vascular inflammation and atherosclerotic
changes [30], which also leads to increased blood pres-
sure. Increased oxidative stress and decreased vasodila-
tion are also attributable to an increase in visceral fat
[31]. In addition, insulin has vasodilatory functions and
aids the kidney in reabsorbing sodium. Insulin resistance
has negative effects in vasodilation, but retains its renal
effect, thereby further elevating blood pressure [32].
In our KoGES cohort, the prevalence of MetS was
15.0% for non-menopausal and 27.6% for menopausal
subjects. According to the 2005 Korean National Health
and Nutrition Examination Survey (KNHANES), the
prevalence of MetS was 14.5% for women aged 40–49
and 37.8% for those aged 50–59 [33]. As the prevalence
of MetS is similar in the KoGES cohort and the
KNHANES 2005, the results of this study may be applic-
able to the general Korean population.
Additionally, data from KNHANES 1998–2008 show
that the prevalence of low HDL-cholesterol in the over-
all population increased to over 60% in the Korean
population. Furthermore, low HDL-cholesterol levels
were more frequent in females than in males [34]. Our
findings with the female population of KoGES are con-
sistent with this general trend. The average level of
HDL-cholesterol was lower than 50 mg/dL in both
non-menopausal and menopausal subjects in our cohort.
Kim et al. also reported that presence of low
HDL-cholesterol was the most frequent component of
MetS in Korean females, but was not significantly asso-
ciated with menopause after adjusting for age [14].
Our study has several limitations. First, menopausal
status was self-reported and data for more objective and
detailed assessment of menopause were missing in the
KoGES registry. Levels of serum FSH were not mea-
sured, and questionnaires did not include information
about gynecologic operations such as hysterectomy or
oophorectomy. Secondly, for many of the subjects, infor-
mation on the use of anti-hypertensive medications were
unavailable. Thus, we only focused on the prevalence of
hypertension, rather than changes in SBP and DBP
values. We also excluded subjects who did not provide
required data and performed analysis on a per protocol
set, which could have resulted in selection bias. Lastly,
hormonal changes during the peri-menopausal period
can bring about metabolic syndrome, but also has effects
on the renin-angiotensin system and affects production
of angiotensin and sodium metabolism, which in turn
can also lead to hypertension [31, 35]. Our study
suggests that metabolic syndrome has a positive rela-
tionship with hypertension in peri-menopausal women,
but the complex mechanism to hypertension could not
be fully assessed in our analysis.
The finding that MetS is a risk factor for development of
hypertension in peri-menopausal women has clinical impli-
cations. Menopause is an aging process and is closely re-
lated with central obesity and development of MetS.
However, we may be able to prevent the development of
other co-morbidities such as hypertension, if we are able to
control MetS. Reducing excessive energy intake and enhan-
cing physical activity is needed to deal with hypertension
near menopausal age. Our study provides the evidence for
more strict monitoring and treatment of central obesity
and insulin resistance in this specific population.
Conclusions
Closely monitoring and treating metabolic syndrome in
women near menopause could help prevent hypertension.
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